Paper Details

  1. Home
  2. Paper Details

Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial.

Author: BahlisNizar, BladéJoan, CavoMichele, ClemensPamela L, De StefanoValerio, FlogegardMax, GrosickiSebastian, HeuckChristoph, HulinCyrille, HungriaVania, IidaShinsuke, KaiserMartin, KorenkovaSibirina, LantzKristen, LaubachJacob, LegiecWojciech, MagenHila, MastersonTara, MateosMaria-Victoria, MoreauPhilippe, NahiHareth, O'RourkeLisa, ParasrampuriaDolly A, QiMing, QinXiang, SpickaIvan, UsmaniSaad Z, VorobyevVladimir, WhiteDarrell, XuSteven, YuanZhilong

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This study (COLUMBA) evaluated the non-inferiority of subcutaneous daratumumab to intravenous daratumumab for the treatment of patients with multiple myeloma. Subcutaneous daratumumab is considered easier to administer and may cause fewer administration-related reactions.
Paper Details　
Original Abstract of the Article :
Intravenous daratumumab for treatment of patients with multiple myeloma involves a lengthy infusion that affects quality of life, and infusion-related reactions are common. Subcutaneous daratumumab is thought to be easier to administer and to cause fewer administration-related reactions. In this stu...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/S2352-3026(20)30070-3

データ提供：米国国立医学図書館（NLM）

Subcutaneous vs. Intravenous Daratumumab: A New Frontier in Multiple Myeloma Treatment

Intravenous daratumumab, a promising treatment for multiple myeloma, often involves a lengthy infusion process that can negatively impact quality of life. This study explored the non-inferiority of subcutaneous daratumumab compared to intravenous daratumumab in patients with relapsed or refractory multiple myeloma. The researchers conducted a multicenter, open-label, non-inferiority, randomized, phase 3 trial to compare the efficacy and safety of these two administration routes.

Subcutaneous Daratumumab: A More Convenient and Potentially Safer Option

The study confirmed the non-inferiority of subcutaneous daratumumab to intravenous daratumumab, demonstrating similar effectiveness in treating patients with multiple myeloma. Subcutaneous administration also offered the added benefits of a simpler and more convenient delivery method, potentially leading to fewer administration-related reactions.

A Shifting Landscape in Myeloma Treatment: Seeking New Pathways

This study represents a significant advancement in the treatment of multiple myeloma. The findings suggest that subcutaneous daratumumab could be a viable alternative to intravenous administration, offering a more convenient and potentially safer approach. This study highlights the ongoing evolution of cancer treatment, with new and innovative approaches constantly emerging to improve patient outcomes.

Dr.Camel's Conclusion

The desert of multiple myeloma research is vast and complex, but the journey to find effective treatments continues. This study offers a new pathway, revealing the potential of subcutaneous daratumumab as a viable and potentially more convenient treatment option. It's a testament to the ongoing progress in cancer research, with new and innovative approaches constantly emerging to improve patient outcomes.

Date :
  1. Date Completed 2020-05-26
  2. Date Revised 2020-05-26
Further Info :

Pubmed ID

32213342

DOI: Digital Object Identifier

10.1016/S2352-3026(20)30070-3

Related Literature

Article Analysis
・Effects of daratumumab injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.